Phase 2 Major Depressive Disorder (MDD) Clinical Trials
17 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–17 of 17 trials
Recruiting
Phase 2
Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression
Major Depressive Disorder (MDD)Probiotic Intervention
First Affiliated Hospital of Chongqing Medical University60 enrolled2 locationsNCT07539805
Recruiting
Phase 2
Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression
Major Depressive Disorder (MDD)Probiotic Intervention
First Affiliated Hospital of Chongqing Medical University120 enrolled1 locationNCT07645157
Recruiting
Phase 2
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Major Depressive Disorder (MDD)Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.153 enrolled21 locationsNCT07284667
Recruiting
Phase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
DepressionMajor Depressive Disorder (MDD)Major Depressive Episode (MDE)
Tonix Pharmaceuticals, Inc.360 enrolled25 locationsNCT07621237
Recruiting
Phase 2
Inhaled DMT for Major Depressive Disorder
SuicideSuicidal IdeationMajor Depression+2 more
Universidade Federal do Rio Grande do Norte140 enrolled5 locationsNCT07562191
Recruiting
Phase 2
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
Major Depressive Disorder (MDD)
Draig Therapeutics Ltd118 enrolled2 locationsNCT07610473
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress
Seaport Therapeutics360 enrolled59 locationsNCT07065240
Recruiting
Phase 2Phase 3
Understanding and Treating Suicidal Ideation With Ketamine
Suicidal IdeationMajor Depressive Disorder (MDD)
The Royal's Institute of Mental Health Research36 enrolled1 locationNCT06891300
Recruiting
Phase 2
Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)
Major Depressive Disorder (MDD)Insomnia Comorbid to Psychiatric Disorder
Unity Health Toronto30 enrolled1 locationNCT06843187
Recruiting
Phase 2
Psilocybin Therapy for Psychological Distress in Palliative Patients
COPD, Chronic Obstructive Pulmonary DiseaseMajor Depressive Disorder (MDD)ALS (Amyotrophic Lateral Sclerosis)+2 more
University Medical Center Groningen108 enrolled4 locationsNCT06782724
Recruiting
Phase 2
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Major Depressive Disorder (MDD)
Draig Therapeutics Ltd300 enrolled40 locationsNCT07300969
Recruiting
Phase 2
A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression
Major Depressive Disorder (MDD)
Daniel Lindqvist12 enrolled1 locationNCT07396272
Recruiting
Phase 2
Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder
Major Depressive Disorder (MDD)
Roger McIntyre30 enrolled1 locationNCT07523048
Recruiting
Phase 2
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
Major Depressive Disorder (MDD)
Supernus Pharmaceuticals, Inc.230 enrolled1 locationNCT07226661
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior
Major Depressive Disorder (MDD)
Sichuan Purity Pharmaceutical Technology Co., Ltd.98 enrolled8 locationsNCT07193901
Recruiting
Phase 2
Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
Major Depressive Disorder (MDD)Suicide Risk
Marianne Goodman30 enrolled1 locationNCT06854224
Completed
Phase 2
Assessing the effects of Lysergic acid diethylamide (LSD) microdosing in people experiencing depression (LSDDEP2)
Major Depressive Disorder (MDD)
The University of Auckland90 enrolled1 locationACTRN12624000128594